<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450944</url>
  </required_header>
  <id_info>
    <org_study_id>2005-536</org_study_id>
    <secondary_id>P30CA013330</secondary_id>
    <secondary_id>AECM-CCI-2005-536</secondary_id>
    <secondary_id>AECM-CCI-05-428</secondary_id>
    <secondary_id>AECM-MMC-05-10-265C</secondary_id>
    <nct_id>NCT00450944</nct_id>
    <nct_alias>NCT00272298</nct_alias>
  </id_info>
  <brief_title>Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express&#xD;
      CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment&#xD;
      for B-cell acute lymphoblastic leukemia.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of anti-CD19 and&#xD;
      anti-CD22 immunotoxins in treating patients with refractory or relapsed B-cell acute&#xD;
      lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of deglycosylated ricin A chain-conjugated&#xD;
           anti-CD19 and anti-CD22 immunotoxins (Combotox) in patients with refractory or relapsed&#xD;
           B-cell acute lymphoblastic leukemia.&#xD;
&#xD;
        -  Determine the toxicity of Combotox in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic (PK) profile of Combotox in these patients.&#xD;
&#xD;
        -  Determine any antitumor activity of Combotox, in terms of the percentage of blasts in&#xD;
           bone marrow and peripheral blood.&#xD;
&#xD;
        -  Determine the levels of human antimouse and human anti-dgA antibodies in patients&#xD;
           treated with Combotox.&#xD;
&#xD;
        -  Determine if there is a correlation between PK parameters and toxicity of Combotox in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine if the expression of the CD19 and CD22 cell surface antigens is affected by&#xD;
           Combotox.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins&#xD;
      (Combotox) IV over 4 hours on days 1, 3, and 5 in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of patients receive escalating doses of Combotox until the maximum tolerated dose is&#xD;
      determined.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2006</start_date>
  <completion_date type="Actual">April 1, 2010</completion_date>
  <primary_completion_date type="Actual">October 27, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimum dose of deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of treatment</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins</intervention_name>
    <arm_group_label>Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adult acute lymphoblastic leukemia&#xD;
&#xD;
               -  B-cell lineage&#xD;
&#xD;
          -  Refractory or relapsed disease based on a bone marrow/peripheral blood examination,&#xD;
             cytogenetic studies, or polymerase chain reaction amplification&#xD;
&#xD;
               -  Disease refractory to conventional therapy and other therapies of higher priority&#xD;
&#xD;
          -  At least 50% of the blasts (in bone marrow or peripheral blood) expressing CD19 and/or&#xD;
             CD22 by flow cytometry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 2 months&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times normal&#xD;
&#xD;
          -  ALT or AST &lt; 2.5 times normal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior chemotherapy, biologic therapy, and/or radiotherapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Verma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

